Top Markets
Coin of the day
Becton, Dickinson and Company Becton, Dickinson and Company

Becton, Dickinson and Company

BDX
Rankning i aktier #492
Operating globally, Becton, Dickinson and Company (BD) is a prominent... Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Aktiekurs
$183.43
Marknadsvärde
$50.54B
Förändring (1 dag)
2.13%
Förändring (1 år)
29.20%
Land
US
Handel Becton, Dickinson and Company (BDX)

Kategori

Intäkter för Becton, Dickinson and Company (BDX)
Intäkter i Jun 2026 TTM: $20.84B
Enligt Becton, Dickinson and Company senaste finansiella rapporter är företagets nuvarande intäkter (TTM) $20.84B. År 2024 hade företaget intäkter på $20.18B en ökning jämfört med intäkterna år 2023, som var $19.37B. Intäkter är det totala belopp som ett företag genererar från försäljning av varor eller tjänster. Till skillnad från vinst dras inga kostnader av.
Intäkts­historik för Becton, Dickinson and Company från 2000 till 2026
Intäkter vid slutet av varje år
År Intäkter Ändra
2026 (TTM) $20.84B -4.58%
2025 $21.84B 8.23%
2024 $20.18B 4.16%
2023 $19.37B 2.66%
2022 $18.87B -1.36%
2021 $19.13B 19.02%
2020 $16.07B -7.03%
2019 $17.29B 8.18%
2018 $15.98B 32.17%
2017 $12.09B -3.12%
2016 $12.48B 21.41%
2015 $10.28B 21.74%
2014 $8.45B 4.87%
2013 $8.05B 4.49%
2012 $7.71B 1.64%
2011 $7.58B 6.45%
2010 $7.12B 1.97%
2009 $6.99B -1.25%
2008 $7.07B 11.25%
2007 $6.36B 10.83%
2006 $5.74B 5.97%
2005 $5.41B 9.73%
2004 $4.93B 10.56%
2003 $4.46B 12.70%
2002 $3.96B 5.49%
2001 $3.75B 3.76%
2000 $3.62B 0.00%
Intäkter för liknande företag eller konkurrenter
Företag Intäkter Intäktsdifferens Land
$11.03B -47.05%
US
$34.74B 66.69%
FR
- -
JP
- -
CH
- -
US